(IN BRIEF) A new study led through collaboration between The Institute of Cancer Research, the Karolinska Institute, and Uppsala University has found that some cases of iAMP21, a rare high-risk subtype of paediatric acute lymphoblastic leukaemia, may begin before birth. … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged all®, bone marrow, cancer evolution, Center for Medical Mass Screening in Sweden, childhood cancer research, childhood leukaemia, chromosome 21 amplification, clonal evolution, Dr Gustaf Leijonhufvud, Dr Tony Ford, Dr Viktor Ljungström, Early Detection, genetic alterations, genetic rearrangement, Haematologica, heel prick tests, high-risk leukaemia, iAMP21, ICR, intrachromosomal amplification of chromosome 21, Karolinska Institute, Karolinska University Hospital, London, lymphocytes, May 26 2026, neonatal blood spots, New ICR-Led Research Traces Early Genetic Origins of High-Risk Childhood Leukaemia to Neonatal Blood Samples, New Study Shows Neonatal Blood Spots Can Reveal Early Genetic Alterations Associated with iAMP21 Leukaemia, paediatric acute lymphoblastic leukaemia, paediatric cancer, pre-ALL clone, pre-leukaemic changes, prenatal origins, Professor Britt Gustafsson, Professor Sir Mel Greaves, Researchers Uncover Evidence That Rare Childhood Leukaemia Subtype Can Begin Years Before Diagnosis, Sweden, Swedish Childhood Cancer Society, The Institute of Cancer Research, The Institute of Cancer Research Study Finds Rare Childhood Leukaemia Subtype Can Begin Before Birth, The Institute of Cancer Research Study Finds Rare Childhood Leukaemia Subtype May Originate Before Birth, United Kingdom, Uppsala University
(PRESS RELEASE) CAMBRIDGE, 29-Sep-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced its rare diseases arm Alexion has exercised its option to acquire all remaining equity in Caelum Biosciences, Inc., a Clinical Stage … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged abnormal antibody, acquisition, AL amyloidosis, Alexion, amyloids, AstraZeneca, bone marrow, CAEL-101, Caelum Biosciences, Cardiac Amyloid Reaching for Extended Survival, CARES Phase III clinical programme, defective plasma cells, IIIb disease, immunoglobulin, light chain (AL) amyloidosis, mAb, Marc Dunoyer, Mayo stage IIIa, monoclonal antibody, rare disease
The new immunotherapy will be tested in humans as soon as possible (PRESS RELEASE) ZURICH, 8-May-2020 — /EuropaWire/ — University of Zurich researchers have announced a study that is showing how hematopoietic stem cells from a healthy donor can help … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged acute leukemia, Acute myeloid leukemia, Alexander Simonis, AML, Antonia M. Müller, blood stem cells, bone marrow, Burkhard Becher, C. Matthias Wilk, Cancer, cancerous hematopoietic stem cells, CAR-T, chemotherapy, Chiara F. Magnani, Christian Münz, Dario Neri, Donal McHugh, ETH Zurich, genetic modification, hematology, Hematopoietic stem cells, immunotherapy, Jonathan D. Kiefer, Juliane Friemel, leukemia, Maries van den Broek, Markus G. Manz, Markus Manz, Nicolás Nuñez, Norman F. Russkamp, oncology, platelets, radiotherapy, red blood cells, Renier Myburgh, Surema Pfister, transplant, University Hospital Zurich, University of Zurich, white blood cells
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?